Trial register facet
Trial records for Semaglutide, oral
20 records for Semaglutide, oral, of which 4 are published trials.
Showing 0 records on this page
Records
20 documents
Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.
| Record | Compound | Phase | Status | Design | Randomised | Year | Certainty |
|---|---|---|---|---|---|---|---|
| SOUL | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 9,650 | 2025 | Moderate |
| SOUL-RENAL-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SOUL-PKprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| SOUL-DDIprogramme record | Semaglutide, oral | Phase 1 | Reported | Randomised crossover | — | 2025 | Very low |
| SOUL-HEPATIC-IMPprogramme record | Semaglutide, oral | Phase 1 | Reported | Phase 1 ascending dose | — | 2025 | Very low |
| OASIS-1 | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 667 | 2023 | Moderate |
| OASIS-1-OLEprogramme record | Semaglutide, oral | Phase 3 | Reported | Single-arm open-label | — | 2023 | Very low |
| OASIS-1-BIOMARKERprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2023 | Very low |
| OASIS-1-ADHERENCEprogramme record | Semaglutide, oral | Phase 3 | Reported | Observational | — | 2023 | Very low |
| PIONEER-1 | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | 703 | 2019 | High |
| PIONEER-6 | Semaglutide, oral | Phase 3 | Reported | Event-driven cardiovascular outcome trial | 3,183 | 2019 | High |
| PIONEER-1-REGIONAL-CNprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-BIOMARKERprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-1-QOLprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-ADHERENCEprogramme record | Semaglutide, oral | Phase 3 | Reported | Observational | — | 2019 | Very low |
| PIONEER-1-BODY-COMPprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-OLEprogramme record | Semaglutide, oral | Phase 3 | Reported | Single-arm open-label | — | 2019 | Very low |
| PIONEER-1-REGIONAL-JPprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-ELDERLYprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |
| PIONEER-6-REGIONAL-JPprogramme record | Semaglutide, oral | Phase 3 | Reported | Randomised, double-blind, placebo-controlled | — | 2019 | Very low |